119 related articles for article (PubMed ID: 35510953)
1. Antitumor Activity of RXDX-105 in Multiple Cancer Types with
Li GG; Somwar R; Joseph J; Smith RS; Hayashi T; Martin L; Franovic A; Schairer A; Martin E; Riely GJ; Harris J; Yan S; Wei G; Oliver JW; Patel R; Multani P; Ladanyi M; Drilon A
Clin Cancer Res; 2017 Jun; 23(12):2981-2990. PubMed ID: 28011461
[No Abstract] [Full Text] [Related]
2. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
Plenker D; Riedel M; Brägelmann J; Dammert MA; Chauhan R; Knowles PP; Lorenz C; Keul M; Bührmann M; Pagel O; Tischler V; Scheel AH; Schütte D; Song Y; Stark J; Mrugalla F; Alber Y; Richters A; Engel J; Leenders F; Heuckmann JM; Wolf J; Diebold J; Pall G; Peifer M; Aerts M; Gevaert K; Zahedi RP; Buettner R; Shokat KM; McDonald NQ; Kast SM; Gautschi O; Thomas RK; Sos ML
Sci Transl Med; 2017 Jun; 9(394):. PubMed ID: 28615362
[TBL] [Abstract][Full Text] [Related]
3. Advances in Targeting RET-Dependent Cancers.
Subbiah V; Cote GJ
Cancer Discov; 2020 Apr; 10(4):498-505. PubMed ID: 32094155
[No Abstract] [Full Text] [Related]
4. Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.
Rosen EY; Won HH; Zheng Y; Cocco E; Selcuklu D; Gong Y; Friedman ND; de Bruijn I; Sumer O; Bielski CM; Savin C; Bourque C; Falcon C; Clarke N; Jing X; Meng F; Zimel C; Shifman S; Kittane S; Wu F; Ladanyi M; Ebata K; Kherani J; Brandhuber BJ; Fagin J; Sherman EJ; Rekhtman N; Berger MF; Scaltriti M; Hyman DM; Taylor BS; Drilon A
Nat Commun; 2022 Apr; 13(1):1936. PubMed ID: 35383193
[No Abstract] [Full Text] [Related]
5. Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.
Offin M; Guo R; Wu SL; Sabari J; Land JD; Ni A; Montecalvo J; Halpenny DF; Buie LW; Pak T; Liu D; Riely GJ; Hellmann MD; Benayed R; Arcila M; Kris MG; Rudin CM; Li BT; Ladanyi M; Rekhtman N; Drilon A
JCO Precis Oncol; 2019; 3():. PubMed ID: 31192313
[No Abstract] [Full Text] [Related]
6. Mitochondrial-Encoded Complex I Impairment Induces a Targetable Dependency on Aerobic Fermentation in Hürthle Cell Carcinoma of the Thyroid.
Frank AR; Li V; Shelton SD; Kim J; Stott GM; Neckers LM; Xie Y; Williams NS; Mishra P; McFadden DG
Cancer Discov; 2023 Aug; 13(8):1884-1903. PubMed ID: 37262072
[TBL] [Abstract][Full Text] [Related]
7. Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.
Chiosea S; Hodak SP; Yip L; Abraham D; Baldwin C; Baloch Z; Gulec SA; Hannoush ZC; Haugen BR; Joseph L; Kargi AY; Khanafshar E; Livhits MJ; McIver B; Patel K; Patel SG; Randolph GW; Shaha AR; Sharma J; Stathatos N; van Zante A; Carty SE; Nikiforov YE; Nikiforova MN
J Clin Endocrinol Metab; 2023 Oct; 108(11):2999-3008. PubMed ID: 37071871
[TBL] [Abstract][Full Text] [Related]
8. Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer.
Chen W; Dream S; Leung PY; Wu PK; Wong S; Park JI
NPJ Precis Oncol; 2024 Feb; 8(1):39. PubMed ID: 38378752
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of cancers derived from thyroid follicular cells.
Fagin JA; Krishnamoorthy GP; Landa I
Nat Rev Cancer; 2023 Sep; 23(9):631-650. PubMed ID: 37438605
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.
Rocco D; Sapio L; Della Gravara L; Naviglio S; Gridelli C
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768754
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy of RET fusion-positive non-small cell lung cancer.
Shen Z; Qiu B; Li L; Yang B; Li G
Front Oncol; 2022; 12():1033484. PubMed ID: 36582799
[TBL] [Abstract][Full Text] [Related]
12. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS
Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490
[TBL] [Abstract][Full Text] [Related]
13. [RET Gene Alterations in Thyroid Cancer-Towards Treatment with Selective RET Inhibitors].
Mitsutake N; Nakamura K; Suzuki S
Gan To Kagaku Ryoho; 2023 May; 50(5):611-614. PubMed ID: 37218322
[TBL] [Abstract][Full Text] [Related]
14. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
15. Targeting RET alterations in cancer: Recent progress and future directions.
Shabbir A; Kojadinovic A; Shafiq T; Mundi PS
Crit Rev Oncol Hematol; 2023 Jan; 181():103882. PubMed ID: 36481304
[TBL] [Abstract][Full Text] [Related]
16. Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
Zheng H; Chen ZS; Li J
Drugs Today (Barc); 2021 Oct; 57(10):621-629. PubMed ID: 34713870
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer.
Raman R; Villefranc JA; Ullmann TM; Thiesmeyer J; Anelli V; Yao J; Hurley JR; Pauli C; Bareja R; Wha Eng K; Dorsaint P; Wilkes DC; Beg S; Kudman S; Shaw R; Churchill M; Ahmed A; Keefer L; Misner I; Nichol D; Gumpeni N; Scognamiglio T; Rubin MA; Grandori C; Solomon JP; Song W; Mosquera JM; Dephoure N; Sboner A; Elemento O; Houvras Y
J Exp Med; 2022 Jun; 219(6):. PubMed ID: 35510953
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
